Expression and significance of TGF-β isoform and VEGF in osteosarcoma

Orthopedics

Volumn 28, Issue 8, 2005, Pages 755-760

  Jung, Sung Taek ^a   Moon, Eun Sun ^a   Seo, Hyoung Yeon ^a   Kim, Jong Seok ^a   Kim, Gye Jin ^a   Kim, Yang Kyung ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; ISOPROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; VASCULOTROPIN;

ADOLESCENT; ADULT; ARTICLE; BONE METASTASIS; CALCANEUS; CANCER SURVIVAL; CHONDROSARCOMA; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FEMALE; FEMUR TUMOR; FIBROSARCOMA; FIBULA; FOLLOW UP; HUMAN; HUMAN TISSUE; HUMERUS; ILIAC BONE; IMMUNOHISTOCHEMISTRY; MALE; METATARSAL BONE; OSTEOSARCOMA; PREVALENCE; PROGNOSIS; PROTEIN EXPRESSION; RADIUS; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; TIBIA;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOSARCOMA; PROGNOSIS; PROTEIN ISOFORMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23844432307     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol. 2001; 8:260-267.
2. Bacci G, Ferrari S, Bertoni F, et al. Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotheapy. Clin Orthop. 2001; 386:186-196.
3. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Osteogenic Sarcoma Preoperative Chemotherapy. 1983; 43:2163-2177.
4. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000; 6:572-577.
5. Lee YH, Tokunaga T, Oshika Y, et al. Cell-retained isoforms of vascular endothelial growth factor(VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer. 1999; 35:1089-1093.
6. Bonewald LF. Transforming growth factor-β. In: Bilezikian JP, Rodan GA, Raisz, ed. Principles of Bone Biology. 2nd ed. 2002:903-918.
7. Van Obberghen-Schilling E, Roche NS, Flanders KC, Sporn MB, Roberts AB. Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells. J Biol Chem. 1988; 263:7741-7746.
8. Bottner M, Krieglstein K, Unsicker K. The transforming growth factor-betas: structure, signaling, and roles in nervous system development and functions. J Neurochem. 2000; 75:2227-2240.
9. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop. 2002; 397: 0-52.
10. Webb CP, Vande Woude GF. Genes that regulate metastasis and angiogenesis. J Neuroncol. 2000; 50:71-87.
11. Foukas AF, Deshmukh NS, Grimer RJ, Mangham DC, Mangos EG and Taylor S : Stage-IIB osteosarocmas around the knee. A study of MMP-9 in surviving tumour cells. J Bone Joint Surg Br. 2002; 84:706-711.
12. Chang HL, Gillett N, Figari I, Lopez AR, Palladino MA, Derynck R. Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res. 1993; 153:4391-4398.
13. Franchi A, Arganini L, Baroni G, et al. Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF-beta1 with high-grade osteosarcomas. J Pathol. 1998; 185:284-289.
14. Franchi A, Benvenuti S, Masi L, et al. TGF-beta isoform and receptor expression in giant cell tumor and giant cell lesions of bone. Appl Immunohistochem Mol Morphol. 2001; 9:170-175.
15. Arrick BA, Lopez AR, Elfman F, Ebner R, Damsky CH, Derynck R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1. J Cell Biol. 1992; 118: 715-726.
16. Robey PG, Young MF, Flanders KC, et al. Osteoblasts synthesize and respond to transforming growth factor-type beta (TGF-beta) in vitro. J Cell Biol. 1987; 105:457-463.
17. Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ. Expression of transforming growth factor-beta (TGF-beta) receptors, TGF-beta 1 and TGF-beta 2 production and autocrine growth control in osteosarcoma cells. Int J Cancer. 1994; 58:440-445.
18. Pfeilschifter J, D'Souza SM, Mundy GR. Effects of transforming growth factor-beta on osteoblastic osteosarcoma cells. Endocrinology. 1987; 121:212-218.
19. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001; 19:1207-1225.
20. Subramaniam M, Oursler MJ, Rasmussen K, Riggs BL, Spelsberg TC. TGF-beta regulation of nuclear proto-oncogenes and TGF-β gene expression in normal human osteoblast-like cells. J Cell Biochem. 1995; 52:52-61.